INTRODUCTION
Depression is a multi-dimensional situation containing depressive mood, psychomotor disorders, sleep disorders, somatic, pain, and anxiety symptoms 1 . This presentation may be affected by age and sex 2 . It has been claimed that this condition will would be the second most prevalent after cardiovascular disorders in human health in the near future 3 . The life time prevalence of depression in Europe has been reported to be 14% 4 . According to "The national disease burden and cost-effectiveness study" depression is the 4 th cause of disease burden in Turkey 5 . Moreover, one third of major depressive disorder patients do not respond to treatment 6 .
Pain is the most common presenting somatic symptom in medical outpatients 7 . However in patients with depression, unexplained painful physical symptoms or medically unexplained pain complaints are common 8 . On average, 65% of patients with depression experience one or more pain complaints, and depression is present in 5% to 85% (depending on the study setting) of patients with pain conditions 9 . In the past, tricyclic antidepressants were used in patients reporting painful physical symptoms or to relieve organic pain, like neuropathic pain. They have been often prescribed in patients with painful conditions without depressive symptoms 10 . In the meantime there is a growing body of evidence that double acting antidepressants (Selective Norepinephrine Reuptake Inhibitors -SNRIs) and dopaminergic substances have higher efficiency in relieving painful symptoms (of organic origin or unexplained) with or without depression 11 . A m o n g t h e m d u l o x e t i n e , v e n l a f a x i n e , mirtazapine, milnacipran, bupropion, and tetracyclic antidepressants as well as MAO inhibitors are recommended for this treatment 12 . Antinociceptive actions of melatonin (MT) have been well demonstrated in a number of animal studies by using different types of models including acute pain, inflammatory pain and neuropathic pain 13 . Not only melatonin but also melatonin agonists such as 2-bromomelatonin 14 , 6-chloromelatonin 15 and certain other pyrrolol indole derivatives of melatonin also exert significant anti-inflammatory and analgesic activity 13 . In this context, it has been suggested that the novel melatonergic antidepressant agomelatine might have a promising role in treating neuropathic pain associated with inflammation and nerve injury 13 . Agomelatine (N-[2-(7-methoxy-1-naphthyl) ethyl] acetamide, S-20098) is a new drug entering psychiatric practice as antidepressant which is analog of melatonin (MT) 16 . It is a selective agonist of MT 1 and MT 2 receptors like melatonin, but additionally has antagonist effect on 5-hydroxytryptamine 2B and 2C (5-HT 2B and 5-HT 2C ) receptors 17 . It is known that activation of 5-HT receptors leads to hyperalgesia 18 . Melatonin a n d s o m e a n t i d e p r e s s a n t s ( m i a n s e r i n , mirtazapine, and amitriptyline) have antagonist effects on 5-HT 2C receptors and also have analgesic effect 17, 19 . Nevertheless, no information about the nociceptive effect of agomelatine was found in the literature. The aim of this study was to determine the possible effect of agomelatine on the nociceptive system.
METHODS
The study was approved by the Ethics Committee of Kafkas University (Approval No.
2012-27).
Animals: Twenty-four healthy male, Swiss albino mice, (aged 4 months old and 28.8±1.18 g weight) were used in this study. The animals were placed in a room with a uniform warm (20) (21) 0 C) temperature and a 12 hour light-dark cycle.
Hot Plate Test:
This method has previously been used in similar research [20] [21] [22] [23] [24] [25] . The animals were placed on the hot plate, which was in an open glass cylinder whose dimension was 17x20 cm. The temperature of the plate was adjusted to 50 o C. When the animal was placed on the plate surface, the test was started and then the reaction time was measured (hind paw licking or jumping). The surface was cleaned after each measurement with 20% of ethanol. The animals were kept on the plate for a maximum 45 seconds to avoid from the heat damage. Thus, values over 45 seconds were regarded as 45 seconds.
Procedure:
The animals were divided into three equal groups (Control, Group A and B) r a n d o m l y. A g o m e l a t i n e w a s g i v e n v i a intraperitoneal injection (i.p.) to groups A and B (0.3 ml, 12.5 mg/kg and 0.3 ml, 25 mg/kg respectively) and 0.3 ml saline solution was given via the i.p. route to the control group. Because of a lack of studies on the effects of agomelatine on the nociceptive system in the literature, those doses were chosen having regard to similar studies [26] [27] [28] 
RESULTS
The hot plate test results were evaluated to reveal nociceptive effects of agomelatine in mice and the pain threshold results are illustrated in Figure 1 and Table 1 .
Primarily, the pain threshold values of the agomelatine groups (A and B) were higher than the control group at each time point (30 th and 60 th minutes). Furthermore, the 30 th minute pain threshold findings of group B were higher than those of group A (p=0.007). In the post-hoc Bonferroni test, the groups were compared (Control and A Groups: p=1, C and B groups: p=0.008, A and B groups: p=0.048). At the last time point (60 th minute) a contrary situation occurred and the pain threshold values of Group A were found to be higher than those of Group B. However, the difference between groups A and B at the 60 th minute were found to be only numerical but not statistically significantly different (p=0.245). According to the statistical data, there were no c o r r e l a t i o n s b e t w e e n t h e C o n t r o l a n d agomelatine groups (between Control and A groups; r=0.197, p=0.356 and between the Control group and group B; r=-0.328, p=0.118).
As regards to the Test of Within-Subject Effect (df=1, F=0.003), there were no statistical difference in terms of time effect on results between the groups (p=0.954) ( Table 2) , but a significant difference in effect was seen between groups (df=2, F=3.996) (p=0.034) ( Table 3 ). In the post-hoc Bonferroni test, significant differences were found between the Control group and group B (p=0.036).
DISCUSSION
In general, depression can be associated with many chronic painful situations [32] [33] [34] . It is known that some antidepressant drugs also have an antinociceptive effect; therefore they can be used for the treatment of painful conditions especially accompanied by depression 20, 33, 35 . Agomelatine is an analogue of melatonin (MT), which is an agonist of MT 1 and MT 2 16,36 . The analgesic effect of melatonin occurs via MT 2 receptors in the nociceptive system 37, 39 . It is known that agomelatine has selective agonistic effects on MT 1 and MT 2 17 . In our study, we found that the agomelatine raised the pain threshold in groups A and B (Figure 1 ). We thought that this might be due to agomelatine's effect on MT 2 receptors. In their study, Yu et al. 38 injected melatonin in rats via the i.p. route and they observed a dose dependent antinociceptive effect. In another study, El-Shenwy et al. 40 found that melatonin had a dose dependent effect increasing the pain threshold in rats. Similarly, we found a dose-dependent effect at the 30 th minute, as anticipated. On the contrary, there was no dose dependent analgesic effect in both groups of agomelatine at the 60 th minute. This may have been due to an insufficient number of mice in the groups. It is known that 5-HT 2B and 5-HT 2C receptors also have a role in pain sensing. Like mianserin, mirtazapine and amitriptyline, some antidepressants also have an antagonistic effect o n t h e s e r e c e p t o r s . T h e r e f o r e , t h e s e antidepressants show analgesic effects on the nociceptive system 17, 41, 42 . In the literature agomelatine has an antagonistic effect as an antidepressant on 5-HT 2B and 5-HT 2C 17 . This information may explain the reason for the increase in the pain threshold in the agomelatine groups. In summary, it can be said that the analgesic effect of agomelatine is due to its agonistic effect on MT 2 along with antagonistic effects on 5-HT 2B and 5-HT 2C receptors. Our study has some limitations. Firstly, it would be better if this study had been performed with more different agomelatine doses. Secondly, the groups should have been larger for a further assessment of agomelatine's effects. However, we couldn't find any studies on the analgesic effects of agomelatine in the literature for assessment of agomelatine doses with a ideal number of mice in the groups.
In conclusion, we have not encountered any studies on analgesic effects of agomelatine in the literature, so we thought that this study could be important to shed light on the direction for future studies. To evaluate the effective doses and to clarify the mechanism of the analgesic effect of a g o m e l a t i n e , m o r e s t u d i e s t h a t a r e comprehensive should be done. Even this study can contribute to an exploration of the relationship between psychiatric disorders and pain. In addition, agomelatine may be a choice of treatment for patients who have painful conditions with or without psychiatric symptoms.
